Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuramis Volume Lidocaine for Mid-Face Volume Augmentation
NCT03754413Completed
- Sponsor
- Medytox Inc.
- Start
- May 2018
- Primary completion
- Mar 2020
- Countries
- 1
01
Overview
Randomised, single-blind trial (2 arms), sponsored by Medytox Inc. Primary endpoint: Facial Volume Scale improvement rate at 24 weeks. Started May 2018; status: completed.
Beyond the preview
Go deeper on NCT03754413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03754413.